Participants were asked whether they had used medication in the past year to manage type 2 diabetes (excluding insulin), reduce the risk of heart disease, or support weight loss and, if so, whether they had used any of five specific GLP-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. This evidence concerns the gene INS and heart disorder.